A Multi-Disciplinary Approach

The care of patients with Liver, Pancreas and Bile Duct disease requires multiple disciplines. To make sure our patients have the best outcomes, each patient's case is discussed among our team of dedicated physicians at weekly conferences. Our team includes a Liver, Pancreas and Biliary Surgery, Hepatology, Interventional Endoscopy, Interventional Radiology, Gastroenterology, Medical Oncology, Radiation Oncology, and an expert Radiologist in body imaging.

Ajax Loader Gif

Ajax Loader Gif

Dr. de la Torre is Director of Liver, Pancreas and Biliary Surgery at St. Joseph's Medical Center. He is also Adjunct Associate Professor of Surgery at Rutgers University, Newark Campus.

Ajax Loader Gif

Medical Doctorate
Johns Hopkins School of Medicine
Baltimore, Maryland
Class of 1989

B.A. Chemistry
Queens College, City University of New York
Flushing, New York
Class of 1984

Visiting Scholar Training Program
Division of Liver Transplant and Hepatobiliary Surgery
(Live Donor Liver Transplant Training)
Asan Medical Center
Seoul, South Korea
March 9-20, 2015

Liver Transplant Fellowship
New Jersey Medical School
University Hospital, University of Medicine & Dentistry of New Jersey
Newark, New Jersey
1999-2000

Kidney and Pancreas Transplant Fellowship
University of Maryland Medical Systems
Baltimore, Maryland
1995-1998

General Surgery Residency
New Jersey Medical School
University Hospital, University of Medicine & Dentistry of New Jersey
Newark, New Jersey
1990-1995
American Board of Surgery 1999, Recertified 2009
Fellow of the American College of Surgeons 2012
35. Mashchenko I, Trtchounian A, Buchholz C, de la Torre AN. A Laparoscopic Sling Technique For Tissue Sparing Resection of Lesions in Segment Seven of the Liver (submitted)

34. de la Torre AN, Contractor S, Castaneda I, Cathcart C, Razdan D, Clyde D, Kisza P, Gonzalez S, Salazar. A Phase I trial using local regional treatment, nonlethal irradiation, intratumoral and systemic polyinosinic-polycytidylic acid polylysine carboxymethylcellulose to treat liver cancer: in search of the abscopal effect. J Hepatocell Carcinoma. 2017 Aug 7;4:111-121

33. de la Torre AN, Castaneda I, Elkholy N, Tham N, Peyton A, Samanta A, Leevy CB.. Patient Targeted Informatics to Increase Blood Testing, Diagnosis and Vaccination in High Risk Populations for Chronic Viral Hepatitis. 2017 Jun 21. JVH [Epub ahead of print]

32.
Lasfer A, Ziosa A, de la Torre AD, Cohen-Solal, KA IFN-λ: A New Inducer of Local Immunity against Cancer and Infections. Frontiers in Immunology 2016 December 15; 7: 598

31. Lasfar A, de la Torre AN, Abushahba W, Cohen-Solal KA, Castaneda I, Yuan Y, Reuhl K, Raveche E, Laskin DL, Kotenko SV. Combination of IFN-α and IFN-λ induce complete remission in BNL hepatoma model: Relevance of IFN-α/λ cross-talk and host immunomodulation. Oncotarget 2016 Aug 2; 7(31): 49259–49267

30 Botros Y, Mathews M, Patel H, Shah N, Baddoura W, de la Torre A Case Report Recurrent Hepatocellular Carcinoma in Patient with Crohn’s Disease: Incidental or Expected Outcome of Azathioprine? . Recurrent Hepatocellular Carcinoma in Patient with Crohn’s Disease: Incidental or Expected Outcome of Azathioprine?. Case Reports in Gastrointestinal Medicine 2015;2015:939136

29. Ambovex® as a novel immunological modulator drug for treatment of Hepato-Cellular Carcinoma (HCC) in liver: Phase II clinical trial. Salama H, Ahmad H, Elchagea I, Zekri RA, Medhat E, Bahnassy A, Lange M, Rabbat M, de la Torre AN, Punamiya P. Journal of Hepatocellular Carcinoma 2015 2:79-89

28. Muir AJ, Shiffman ML, Zaman A, Yoffe B, de la Torre A, Flamm S, Gordon S, Marotta P, Vierling J, Lopez-Talavera JC, Byrnes-Blake K, Fontana D, Freeman J, Gray T, Hausman D, Hunder NN, Lawitz E. Phase 1b Dose- Ranging Study of PEG-Interferon-Lambda Plus Ribavirin in Patients with Chronic Genotype 1 Hepatitis C Virus Infection. Hepatology. 2010 May 14

27. Abushahba W, Lasfar A , Balan M, Castaneda I, Yuan Y, Prescott L, Reuhl K, Raveche E, de la Torre AN, Kotenko SV. Antitumor Activity of Type I and Type III Interferons in BNL Hepatoma Model. Cancer Immunol Immunother. 2010 Mar 9

26. Ferrante JM, Winston DG, Chen PH, de la Torre AD Family Physicians’ Knowledge and Practices Regarding Chronic Hepatitis and Monitoring for Liver Cancer. Family Medicine Family Medicine 2008 May: 40(5), 345-351

25. Koneru B, Shareef A, Dikdan G, Desai K, Klein KM, Peng B, Wachsberg RH, de la Torre AN, Debroy M, Fisher A, Wilson DJ, Samanta AK. The ischemic preconditioningparadox in deceased donor liver transplantation- evidence from a prospectiverandomized single blind clinical trial. Am J Transplant. 2007 Dec;7(12):2788-96.

24. Abujudeh H, Contractor D, delaTorre A, Koneru B. Rescue TIPS in acute Budd-Chiari syndrome. AJR Am J Roentgenol. 2005 Jul;185(1):89-91.

23. Ponnudurai RN, Koneru B, Akhtar SA, Wachsberg RH, Fisher A, Wilson DJ, de la Torre AN. Vasopressor administration during liver transplant surgery and its effect on endotracheal reintubation rate in the postoperative period: a prospective, randomized, double-blind, placebo-controlled trial. Clin Ther. 2005 Feb;27(2):192-8.

22. Koneru B, Fisher A, He Y, Klein KM, Skurnick J, Wilson DJ, de la Torre AN, Merchant A, Arora R, Samanta AK. Ischemic preconditioning in deceased donor liver transplantation: a prospective randomized clinical trial of safety and efficacy. Liver Transpl. 2005 Feb;11(2):196-202.

21. Harrison LE, Reichman T, Koneru B, Fisher A, Wilson D, dela Torre A, Samanta A, Korogodsky M. Racial discrepancies in the outcome of patients with hepatocellular carcinoma. Arch Surg. 2004 Sep;139(9):992-6.

20. de la Torre AN, Fisher A, Wilson DJ, Reitsma W, Goerlitz F, Koneru. Minimally Invasive Optimization of Organ Donor Resuscitation: Case Reports. Prog Transplant. 2005 Mar;15(1):27-32.

19. Fisher A, Seguel JM, de la Torre AN, Wilson D, Merchant A, Arora RK, Koneru B. Effect of sirolimus on infection incidence in liver transplant recipients. Liver Transpl. 2004 Feb;10(2):193-8.

18. Dikdan, GS, Saba SC, de la Torre AD, Roth JR, Wang S, Koneru B. Role of Oxidative Stress in the Increased Activation of Signal Transducers and Activators of Transcription-3 in the Fatty Livers of Obese Zucker Rats. Surgery 2004 136(3):677

17. de la Torre AN, Fisher A, Wilson DJ, Harrison J, Koneru B. A Case Report of Donor to Recipient Transmission of Severe Thrombocytopenia Purpura. Transplantation. 2004 May 15;77(9):1473-4

16. Harrison LE, Koneru B, Baramipour P, Fisher A, Barone A, Wilson D, dela Torre AN, Cho KC, Contractor D, Korogodsky M. Locoregional recurrences are frequent after radiofrequency ablation for Hepatocellular carcinoma. J Am Coll Surg J Am Coll Surg. 2003 Nov; 197(5): 759-64.

15. Monteiro I, McLoughlin LM, Fisher A, dela Torre AN, Koneru B. Rituximab with plasmapheresis and splenectomy in ABO-Incompatible liver transplantation. Transplantation 2003; 76(11):1648

14. Das K, Fisher A, Wilson DJ, dela Torre AN, Seguel J, Koneru B. Primary non-Hodgkin’s lymphoma of the bile ducts mimicking cholangiocarcinoma: Report of two cases and review of the literature. Surgery 2003 Sep; 134(3):496

13. Wilson DJ, Fisher A, Das K, Goerlitz F, Holland BK, de la Torre AN, Merchant A, Seguel J, Samanta AK, Koneru B.. Donors with cardiac arrest: Improved organ recovery but no preconditioning benefit in liver allografts. Transplantation 2003; 75:1683-1687.

12. Koneru B, Fisher A, Wilson DJ, Klein KM, de la Torre AN, Seguel J. De novo pulmonary hypertension following successful liver transplantation. Am J Transplant. 2002 Oct;2(9):883-6.

11. delaTorre A.N., Schroeder R.A., Punzulan C., Kuo P.C.: Endotoxin-mediated S-nitrosylation of p50 alters nf-kappa B-dependent gene transcription in ANA-1 murine macrophages. Journal of Immunology 1999; 162(7): 4101. 1999.

10. delaTorre A.N., Schroeder R.A., Bartlett S.T., Kuo P.C.: Differential Effects of Nitric Oxide-mediated S-nitrosylation on p50 and c-jun DNA Binding. Surgery. 1998; 124(2):137.

9. Kuo P.C., Drachenberg C.I., delaTorre A.N., Bartlett S.T., Lim J.W., Plotkin J.S., Johnson L.B.: Apoptosis and Hepatic Allograft Reperfusion Injury. Clinical Transplantation. 1997; 12(3):219.

8. delaTorre A.N., Schroeder R.A., Kuo P.C.: Alteration of NF-kappa B p50 Binding Kinetics by S-Nitrosylation. Biophysical Bioresearch Communications. 1997; 238(3):703.

7. Bartlett S.T., Schweitzer E.J., Kuo P.C., Johnson L.B., delaTorre A.N., Hadley G.A.: Prevention of Autoimmune Islet Allograft Destruction by Engraftment of Donor T Cells. Transplantation 1997; 63(2):299.

6. Schroeder R.A., delaTorre A.N., Kuo P.C.: A CD14 Dependent Mechanism For Endotoxin-Mediated Nitric Oxide Synthesis In Murine Macrophages. American Journal of Physiology 1997; 273(1):C1030.

5. Bartlett S.T., delaTorre A.N., Johnson L.B., Kuo P.C., Schweitzer E.J.: Long-Term Pancreatic Function: Potential Benefits. Transplantation Proceedings 1997; 28(4):2128.

4. Johnson L.B., Kuo P.C., Schweitzer E.J., Ratner L.E., Klassen D.K., Hoehn-Saric E.W., delaTorre A.N., Weir M.R., Strange J., Bartlett S.T: Double Renal Allografts Successfully Increase Utilization of Kidneys from Older Donors Within a Single Organ Procurement Organization. Transplantation 1997; 62(11):1581.

3. Kuo P.C., delaTorre A.N., Johnson, L.B., Schweitzer, E.J., Bartlett, S.T.: Bilateral Retroperitoneal Renal Allografts: Technique for Placement Through a Midline Incision. Journal of the American College of Surgeons 1997; 183(5):529.

2. delaTorre A.N., Kuo P.C., Plotkin J.S., Ridge L.A., Howell C.D., Bartlett S.T., Johnson L.B.: Influence of Donor Base Deficit Status on Recipient Outcomes in Liver Transplantation. Transplantation Proceeding 1997; 29(1-2):474.

1. Koneru B, Reddy M.C., delaTorre, A.N., Patel P, Ippolito T, Ferrante R.J.: Studies of Hepatic Warm Ischemia in the Obese Zucker Rat. Transplantation 1995; 59(7):942.
A Phase 1 Study to Assess the Safety and Antiviral Activity of PEG-rIL-29 Administered as a Single Agent and in Combination With Ribavirin in Treatment-Relapsed and Treatment-Naive Subjects With Chronic Hepatitis C Virus InfectionSponsor: Zymogenetics NCT00565539
Site Principle Investigator: Study closed
2007

Phase II Pilot Study of Sorafenib Tosylate Before and After Hepatic Arterial Chemoembolization With Doxorubicin Hydrochloride and Mitomycin C in Patients With Localized Unresectable Hepatocellular Carcinoma
Sponsor: Bayer Pharmaceutical, NCT00949182
Principle Investigator: Study completed
2009-2011

Randomized, Controlled Phase 2a/b Study of the Efficacy and Safety of PEG-rIL-29 in Combination With Ribavirin to Treatment-Naive Subjects With Chronic Hepatitis C Virus Infection
Sponsor: Zymogenetics NCT01001754
Site Principle Investigator: Study closed
2009

A Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of DEB025/Alisporivir in Combination With Peg-IFNα2a and Ribavirin in Hepatitis C Genotype 1 Treatment-naïve, 2010
Sponsor: Novartis, NCT01318694
Site Principle Investigator: Study closed
2010-2011

A Randomized, Double Blind, Placebo Controlled, Multicenter Phase 2 Study of VT-122 in Combination With Sorafenib Compared to Sorafenib With Placebo in Patients With Hepatocellular Carcinoma and Systemic Inflammation at Risk for Cachexia. 2011-present
Sponsor: Vicus Therapeutics, NCT01265576
Site Principal Investigator: Study closed
2011-2014

A Multicenter, Randomized, Double-Blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line
Therapy With Sorafenib (REACH). 2012
Sponsor: Eli Lilly and Company, NCT01140347
Site Principle Investigator: Study closed
2011-2012

Characterization Of Focal Liver Lesions With Sonovue®-Enhanced Ultrasound Imaging: A Phase III, Intrapatient Comparative Study Versus Unenhanced Ultrasound Imaging Using Histology Or Combined Imaging/Clinical Data As Truth Standard. 2012
Sponsor: Bracco Diagnostics, Inc, NCT00788697
Site Principal Investigator: Study Closed
2011-2012

Protocol HALO-109-201 is a Phase Ib/II clinical study. Phase Ib will assess the the safety and tolerability, and determine a safe dose of the experimental drug PEGPH20 to use in combination with the standard dose of gemcitabine in patients with Stage IV previously untreated pancreatic cancer. 2011
Sponsor: Halozyme, NCT01453153
Site Principal Investigator
: Study Closed
2013-2015

A Phase 2b randomized, open-label, multi-center trial of Intra tumoral JX-594 administration plus best supportive care (BSC) versus BSC in patients with advanced hepatocellular cancer (HCC) who have failed sorafenib (standard of care drug for HCC) treatment. 2013
Sponsor: Jennerex Biotherapeutics, NCT01387555
Site Principal Investigator
: Study Closed
2013-2014

A Phase 2, Randomized, Multicenter Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Combined With Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Previously Untreated Pancreatic Cancer. 2014
Sponsor: Halozyme, NCT01839487
Site Principal Investigator: Closed
2014-2015

A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 (PDL-1 antagonist) in Subjects With Advanced Solid Tumors. 2014
Sponsor: Medimmune, NCT01693562
Site Principal Investigator: Study in progress
2015

A Phase 3b, Double‑Blind, Randomized, Placebo‑Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Subjects with Primary Biliary Cirrhosis’
Sponsor: Intercept, NCT02308111
Site Principal Investigator: Study in progress
2015-present

A Phase 1/2, Dose-escalation, Open-label, Non-comparative Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Advanced Hepatocellular Carcinoma Subjects with or without Chronic Viral Hepatitis; and a Randomized, Open-label Study of Nivolumab vs Sorafenib in Advanced Hepatocellular Carcinoma Subjects who are Naive to Systemic Therapy
Sponsor: BMS, NCT016588782016
2016-closed

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination with nab-Paclitaxel Plus Gemcitabine Compared with Placebo Plus nab-Paclitaxel and Gemcitabine in Subjects with Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma
Sponsor: Halozyme,
2016-present

A Phase 3 Randomized, Open-Label Study Comparing Pexa Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy
Sponsor: Sillajen, NCT02562755
2016-present

A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis
Sponsor: Intercept, NCT02548351
Site Principal Investigator: Study in progress
2016-present
Gilead
Director: 2016-2018
Automated EMR Based “Baby Boomer” HCV Blood Testing and Region of Birth HBV/HCV Blood Testing in an Urban Culturally Diverse Population Combined with Patient Navigation and Likage to Care

Healthcare Foundation of New Jersey
Principle Investigator: 2011-2012
Use of Audio-Computer Assisted Survey Interview to Increase Viral Hepatitis Screening

Healthcare Foundation of New Jersey
Principle Investigator 2007
A Clinical Approach to Understand the Underdiagnosis and Treatment of Hepatitis C and B

Roche Pharmaceutical
Principle Investigator 2007
Use of Audio-Computer Assisted Survey interview to Engage People in Need of Chronic Viral Hepatitis Blood Testing

Bayer Pharmaceutical
Principle Investigator 2009
Phase II Pilot Study of Sorafenib Tosylate Before and After Hepatic Arterial Chemoembolization With Doxorubicin Hydrochloride and Mitomycin C in Patients With Localized Unresectable Hepatocellular Carcinoma

Gilead Pharmaceutical
Principle Investigator 2009
A Clinical Approach to Understand Obstacles To the Diagnosis of Chronic Viral Hepatitis in Order to Improve Early Diagnosis of Liver Cancer

Human Services and Resources Administration 08-130:
Principle Investigator 2009
Patient Navigation to Increase Access to Chronic Viral Hepatitis Treatment and Liver Cancer Screening in Low Income Urban Communities Subject to Health Disparities

Healthcare Foundation of New Jersey
Principle Investigator: 2010
Support and Optimization of Infrastructure to Reduce Liver Disease Mortality
American Liver Foundation, Medical Advisory Board 2017-present

Medical Advisor Latino Organization for Liver Awareness 2004-2010

Vice Medical Director New Jersey Tissue and Organ Sharing Network 2005-2010

New Jersey State DOH Chronic Viral Hepatitis Advisory Board 2006-present

Board of Directors: New Jersey Tissue and Organ Sharing Network 2007-2010

Vice-Chairman: New Jersey Hep-Help Alliance: October 2008-present



liver cancer treatment in new jersey, liver cancer surgery in new jersey, pancreas cancer surgery in new jersey, bile duct cancer surgery in new jersey, hepatobiliary surgery in new jersey, pancreatitis surgery in new jersey, portal hypertension care in new jersey, mesocaval shunt in new jersey, laparoscopic liver surgery, laparoscopic pancreas surgery, laparoscopic hepatobiliary surgery

HepatoPancreatoBiliary Advanced Practice Nurse
ph: 973-754-2786
fx: 973-754-3528
Patient Coordinator, scheduling and authorizations
ph: 973-754-2315
fx: 973-754-3528
Research Coordinator
ph: 973-972-6812
fx: 862 902-1669

liver cancer treatment in new jersey, liver cancer surgery in new jersey, pancreas cancer surgery in new jersey, bile duct cancer surgery in new jersey, hepatobiliary surgery in new jersey, pancreatitis surgery in new jersey, portal hypertension care in new jersey, mesocaval shunt in new jersey, laparoscopic liver surgery, laparoscopic pancreas surgery, laparoscopic hepatobiliary surgery


Ajax Loader Gif

Director of Hepatology

Dr Maliha Ahmad is a Transplant Hepatologist with 7 years experience at the Rutger's Newark Liver Transplant program. Working at the busiest liver transplant program in New Jersey, she has taken care of thousands of patients with all types of liver disease. She has been a co-investigator on numerous clinical trials.
Hepatology Physician Assistant

Ms Korogodsky worked 10 years in adult liver transplant at the Rutgers Newark Program and 2 years in pediatric liver transplant at Columbia Presbyterian Medical Center.
Medical Assistant
Patient Navigator

Farhan Ayoub oversees our automated EMR order entry program to test all patients born between 1945-1965, "Baby Boomers", with the St Joseph's Health Care System.

liver cancer treatment in new jersey, liver cancer surgery in new jersey, pancreas cancer surgery in new jersey, bile duct cancer surgery in new jersey, hepatobiliary surgery in new jersey, pancreatitis surgery in new jersey, portal hypertension care in new jersey, mesocaval shunt in new jersey, laparoscopic liver surgery, laparoscopic pancreas surgery, laparoscopic hepatobiliary surgery

Ajax Loader Gif

Edward Milman M.D.
Section Chief Diagnostic and Interventional Musculoskeletal Radiology
Director of MRI St Joseph's Hospital Medical Center.

Dr. Milman completed his Medical School education at SUNY Downstate, Brooklyn NY. He continued his training in Radiology as a resident at New York Presbyterian Hospital of Columbia University in New York. He stayed at Columbia University to receive subspecialty training during his Fellowship in Musculoskeletal/Body MRI. Dr. Milman specializes in Hepatobiliary/Musculoskeletal/Body Cross sectional imaging and has special interest and expertise in Cardiac CTA and MRI imaging. He received prestigious "Teacher Of The Year Award" twice for his contribution to education of radiology residents at New York Presbyterian Hospital, NY. He remains an active member of the radiology department as an Adjunct Professor of Radiology at Columbia University. He is certified by American Board of Radiology and holds Clinical Magnetic Resonance Society Certification in Body MRI, Orthopedic MRI and Neuroradiology MRI and also has a RPVI (Registered Physician Vascular Ultrasound Interpretaion) certification.  Dr. Milman is one of handful of NJ Radiologists who are recognized as Level III Coronary CTA certified and Cardiovascular CT board certified- the highest certification available in this field of cardiovascular imaging.

Awards and Recognition
Twice named "Teacher of the Year" New York Presbyterian Hospital 2012 Top Doc Award - NJ Monthly Magazine
Fred Berlin, M.D., RPVI
Vascular and Interventional Radiology

After finishing residency in Diagnostic Radiology at The Mount Sinai School of Medicine in New York, he then went on to receive subspecialty training during his clinical fellowship in Vascular and Interventional Radiology at The Mount Sinai Medical Center. Dr. Berlin has extensive experience and active interest in minimally invasive treatments for liver cancer including Yttrium-90 radioembolization, chemoembolization and thermal ablative therapies. He also focuses on minimally invasive treatments for uterine fibroids, peripheral arterial disease and complex venous revascularization, embolotherapy for hemorrhage and portal venous hypertension therapies such as Transjugular Intrahepatic Portosystemic Shunt (TIPS) and Balloon Occlusion Retrograde Transvenous Obliteration of Gastric Varices (BRTO). Additionally, Dr. Berlin has broad expertise in providing a wide variety of traditional Interventional Radiology procedures such as image guided biopsies, dialysis access, hepatobiliary, genitourinary and gastrointestinal interventions. Dr. Berlin was involved in numerous clinical trials, publications, abstracts and scientific exhibits and has been invited to lecture and present his clinical research in the field of minimally invasive interventions at multiple national conferences all over the country. He is board-certified by the American Board of Radiology in Diagnostic Radiology, is a member of American College of Radiology and Society of Interventional Radiology and has RPVI (Registered Physician Vascular Ultrasound Interpretation) certification.
Interventional Radiology
Interventional Radiology
Diagnostic Radiology

liver cancer treatment in new jersey, liver cancer surgery in new jersey, pancreas cancer surgery in new jersey, bile duct cancer surgery in new jersey, hepatobiliary surgery in new jersey, pancreatitis surgery in new jersey, portal hypertension care in new jersey, mesocaval shunt in new jersey, laparoscopic liver surgery, laparoscopic pancreas surgery, laparoscopic hepatobiliary surgery

Ajax Loader Gif

Interventional Endoscopy

http://www.ganjllc.com/matthew-grossman.php

Training
Advanced Therapeutic Endoscopy Fellowship • Lennox Hill Hospital, New York, NY 2010

Gastroenterology Fellowship 2007-2010 • New York University Medical Center, NY, GI Division

Internal Medicine Internship and Residency • Columbia University Medical Center , New York, NY

UMDNJ Robert Wood Johnson Medical School - New Brunswick NJ • Doctor of Medicine • Alpha Omega Alpha Honors Society

Washington University - St. Louis, MO 1996-2000 • Bachelor of Science • Magnum Cum Laude • Major: Economics, Minor: Biology • Golden Key National Honors Society

Awards
GI fellow of the year 2008 - awarded for excellence in teaching house staff Dr. Howard J. Eddy Scholarship recipient 2008 for exceptional NYSGE GI Presentation NYSGE "fellows night" presentation winner - "Double Pylorus" Digestive Disease Week 2005 Poster of Distinction Alpha Omega Alpha Robert "Wood Johnson Dean's Academic' Scholarship Howard Hughes Summer Research Fellowship
Interventional Endoscopy
Director Gastroenterology Fellowship Program
St. Joseph's Medical Center

liver cancer treatment in new jersey, liver cancer surgery in new jersey, pancreas cancer surgery in new jersey, bile duct cancer surgery in new jersey, hepatobiliary surgery in new jersey, pancreatitis surgery in new jersey, portal hypertension care in new jersey, mesocaval shunt in new jersey, laparoscopic liver surgery, laparoscopic pancreas surgery, laparoscopic hepatobiliary surgery

Ajax Loader Gif

Director of Tumor Board
St. Joseph's Medical Center
Director Medical Oncology Fellowship
St. Joseph's Medical Center

liver cancer treatment in new jersey, liver cancer surgery in new jersey, pancreas cancer surgery in new jersey, bile duct cancer surgery in new jersey, hepatobiliary surgery in new jersey, pancreatitis surgery in new jersey, portal hypertension care in new jersey, mesocaval shunt in new jersey, laparoscopic liver surgery, laparoscopic pancreas surgery, laparoscopic hepatobiliary surgery

liver cancer treatment in new jersey, liver cancer surgery in new jersey, pancreas cancer surgery in new jersey, bile duct cancer surgery in new jersey, hepatobiliary surgery in new jersey, pancreatitis surgery in new jersey, portal hypertension care in new jersey, mesocaval shunt in new jersey, laparoscopic liver surgery, laparoscopic pancreas surgery, laparoscopic hepatobiliary surgery


For an Appointment

Dr de la Torre is no longer with
St Joseph’s

Phone: coming soon
Fax: coming soon






Offices: coming soon